Lexicon Pharmaceuticals LXRX Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's common stock, shares authorized (in shares)?
- Lexicon Pharmaceuticals (LXRX) reported common stock, shares authorized (in shares) of $450M in Q1 2026.
- How has Lexicon Pharmaceuticals's common stock, shares authorized (in shares) changed year-over-year?
- Lexicon Pharmaceuticals's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $450M to $450M.
- What is the long-term trend for Lexicon Pharmaceuticals's common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), Lexicon Pharmaceuticals's common stock, shares authorized (in shares) has grown at a 14.9% compound annual growth rate (CAGR), from $225M to $450M.